Abstract：
This meta-analysis aimed to evaluate the correlation between lncRNA HULC, prognosis and clinicopathological characteristics in patients with digestive system tumors.
The relevant literatures were collected through PubMed, Web of Science and Embase up to February 2021. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the prognostic value of HULC in patients with digestive system tumors. The clinicopathological characteristics of HULC in patients were estimated by odds ratios (ORs).
A total of 14 studies involving 1312 patients were included. The up-regulated expression level of HULC was associated with poorer overall survival (OS) in patients with digestive system tumors (HR = 1.83, 95% CI: 1.05-3.19, P = 0.033). Subgroup analysis showed that cancer type (pancreatic cancer or gastric cancer), residence region (China, Japan or Korea), and specimen (serum) significantly associated between HULC and OS. In addition, high HULC expression significantly increased the risk of high TNM stage (OR = 2.51, 95%CI: 1.36-4.62, P < 0.05), poor differentiation (OR = 1.38, 95%CI: 1.02-1.87, P < 0.05) and lymphatic node metastasis (LNM, OR = 4.93, 95% CI: 3.47-6.99, P < 0.05).
High expression level of HULC is related to OS, TNM stage, differentiation and LNM. Therefore, HULC can be used as a new potential predictor for prognosis and clinicopathological features of patients with digestive system tumors.
The relevant literatures were collected through PubMed, Web of Science and Embase up to February 2021. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the prognostic value of HULC in patients with digestive system tumors. The clinicopathological characteristics of HULC in patients were estimated by odds ratios (ORs).
A total of 14 studies involving 1312 patients were included. The up-regulated expression level of HULC was associated with poorer overall survival (OS) in patients with digestive system tumors (HR = 1.83, 95% CI: 1.05-3.19, P = 0.033). Subgroup analysis showed that cancer type (pancreatic cancer or gastric cancer), residence region (China, Japan or Korea), and specimen (serum) significantly associated between HULC and OS. In addition, high HULC expression significantly increased the risk of high TNM stage (OR = 2.51, 95%CI: 1.36-4.62, P < 0.05), poor differentiation (OR = 1.38, 95%CI: 1.02-1.87, P < 0.05) and lymphatic node metastasis (LNM, OR = 4.93, 95% CI: 3.47-6.99, P < 0.05).
High expression level of HULC is related to OS, TNM stage, differentiation and LNM. Therefore, HULC can be used as a new potential predictor for prognosis and clinicopathological features of patients with digestive system tumors.
摘要：
这项荟萃分析旨在评估lncRNAHULC，消化系统肿瘤患者的预后和临床病理特征。
相关文献是通过PubMed收集的，WebofScience和Embase至2021年2月。计算风险比（HR）和95％置信区间（CIs）以评估HULC在消化系统肿瘤患者中的预后价值。用比值比(OR)估计HULC患者的临床病理特征。
共纳入14项研究，涉及1312名患者。HULC表达上调与消化系统肿瘤患者总生存期(OS)较差相关(HR=1.83,95%CI:1.05~3.19,P=0.033)。亚组分析显示癌症类型（胰腺癌或胃癌），居住地(中国，日本或韩国)，和标本（血清）在HULC和OS之间显着相关。此外,HULC高表达显著增加高TNM分期的风险(OR=2.51,95CI:1.36~4.62,P<0.05),分化差（OR=1.38，95CI：1.02-1.87，P<0.05）和淋巴结转移（LNM，OR=4.93,95%CI:3.47-6.99,P<0.05)。
HULC的高表达水平与OS有关，TNM阶段,分化和LNM。因此,HULC可作为一种新的预测消化系统肿瘤患者预后和临床病理特征的潜在指标。
相关文献是通过PubMed收集的，WebofScience和Embase至2021年2月。计算风险比（HR）和95％置信区间（CIs）以评估HULC在消化系统肿瘤患者中的预后价值。用比值比(OR)估计HULC患者的临床病理特征。
共纳入14项研究，涉及1312名患者。HULC表达上调与消化系统肿瘤患者总生存期(OS)较差相关(HR=1.83,95%CI:1.05~3.19,P=0.033)。亚组分析显示癌症类型（胰腺癌或胃癌），居住地(中国，日本或韩国)，和标本（血清）在HULC和OS之间显着相关。此外,HULC高表达显著增加高TNM分期的风险(OR=2.51,95CI:1.36~4.62,P<0.05),分化差（OR=1.38，95CI：1.02-1.87，P<0.05）和淋巴结转移（LNM，OR=4.93,95%CI:3.47-6.99,P<0.05)。
HULC的高表达水平与OS有关，TNM阶段,分化和LNM。因此,HULC可作为一种新的预测消化系统肿瘤患者预后和临床病理特征的潜在指标。
